Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

The plan for K has always been to get a full characterization. While there was hope that it might work as a stand alone drug, Menon’s strategy was and is to use it in combination with other drugs to enhance their efficacy and extend periods of remission. K may yet work alone against a few resistant or types of cancers with compromised p53, but there is still much work to do through extending systemic exposure as well as more testing in combination. As for an effective drug that repairs and modulates p53, it has been very effective with promising evidence of tumor growth arrest and reduction.